Navigation Links
Alseres Pharmaceuticals, Inc. Reports 2007 Financial Results and Provides Company Highlights
Date:3/31/2008

ical Surgeons (AANS), April 2007;

-- American Spinal Injury Association (ASIA), June 2007;

-- World Spine, July 2007;

-- Congress of Neurological Surgeons, September 2007; and

-- North American Spine Society, October 2007

Advanced the Molecular Imaging Program.

-- In July 2007, Alseres completed a study with our collaborators that

optimized ALTROPANE's image acquisition protocol. We believe the

optimized protocol will enhance ALTROPANE's use once commercialized.

-- After a series of discussions with the FDA and our expert advisors, our

POET-2 program was designed as a two-part Phase III program using the

optimized ALTROPANE image acquisition protocol. The first part of the

program was initiated in December 2007 in a multi-center clinical study

in subjects to acquire a set of ALTROPANE images to train the expert

readers. The second part involves two concurrent, replicate, multi

center Phase III trials. These two concurrent trials will be initiated

once final agreement on the design of the two trials is reached with

the FDA.

-- Data from a study to evaluate the Test/Re-test reliability of ALTROPANE

in Parkinson disease patients were presented at Movement Disorder

Society's 11th International Congress of Parkinson's Disease and

Movement Disorders in June 2007. The data demonstrated that ALTROPANE

uptake is reduced in Parkinson's Disease patients with moderate PD and

has excellent test/re-test reliability.

-- We advanced partnering discussions for our Molecular Imaging Program

the focus of which was the completion of the Phase III clinical

program, development of the product in Dementia with Lewy Bodies,

development of the product in Europe, ultimately the launch and

commercialization of ALTROPANE and product family life cycle managemen
'/>"/>

SOURCE Alseres Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Alseres Pharmaceuticals to Host 2007 Financial Results Conference Call
2. Alseres Pharmaceuticals Presents Inosine and Dopamine Transporter (DAT) Blocker Preclinical Data at the American Society for Experimental NeuroTherapeutics (ASENT) Conference
3. Alseres Pharmaceuticals, Inc. to Present at Windhovers Therapeutic Area Partnerships Conference
4. Alseres Pharmaceuticals, Inc. to Present at Bio Investor Forum 2007 Annual Meeting
5. Aida Pharmaceuticals, Inc. Acquires High-Level Research Institute in the Peoples Republic of China
6. Jazz Pharmaceuticals, Inc. Announces Expansion of Senior Debt
7. ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
8. Jazz Pharmaceuticals, Inc. Announces Webcast of March 13 Investor Meeting
9. Acura Pharmaceuticals, Inc. Reports 2007 4th Quarter and Annual Financial Results; Sets 2008 Expectations
10. Investor Alert from Cauley Bowman Carney & Williams, PLLC: Update on Proposed Acquisition of CollaGenex Pharmaceuticals, Inc. - CGPI
11. Strativa Pharmaceuticals, a Division of Par Pharmaceutical, Announces the Discontinuation of the Development Program for Pafuramidine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2014)... UPTON, NYElectronic devices with unprecedented efficiency and ... materials that use built-in electric polarizations to ... magnets inside most popular data-driven technology. But ... stumbling blocks, including a curious habit of ... at the U.S. Department of Energy,s Brookhaven ...
(Date:8/18/2014)... According to a new ... Science Reagents Market(Products- PCR Reagent Kits, Cell and ... Reagents and Others; End Users- Commercial and Contract ... Forensic Laboratories)- Global Industry Analysis, Size, Share, Growth, ... life science reagents market was valued at USD ...
(Date:8/18/2014)... Aug. 18, 2014 TNI BioTech, Inc. (OTC-BB: ... the manufacturing and marketing of innovative therapies for autoimmune ... is providing a second notice of TNI BioTech,s annual ... the announcement, Noreen Griffin , founder and CEO ... for your participation in the Annual Meeting. On behalf ...
(Date:8/18/2014)... August 18, 2014 China is ... for the clinical research industry. Clinicaltrial.gov statistics highlight ... to its aging population; a high increase in ... a densely populated pool of patients and a ... these positive points, China also presents challenges for ...
Breaking Biology Technology:Promising ferroelectric materials suffer from unexpected electric polarizations 2Promising ferroelectric materials suffer from unexpected electric polarizations 3Promising ferroelectric materials suffer from unexpected electric polarizations 4Global Life Science Reagents Market Expected to Reach USD 25.7 Billion in 2019: Transparency Market Research 2Global Life Science Reagents Market Expected to Reach USD 25.7 Billion in 2019: Transparency Market Research 3Global Life Science Reagents Market Expected to Reach USD 25.7 Billion in 2019: Transparency Market Research 4Global Life Science Reagents Market Expected to Reach USD 25.7 Billion in 2019: Transparency Market Research 5TNI BioTech Inc., provides 2nd Notice of Annual Meeting September 4, 2014 2TNI BioTech Inc., provides 2nd Notice of Annual Meeting September 4, 2014 3TNI BioTech Inc., provides 2nd Notice of Annual Meeting September 4, 2014 4China – Land of Opportunities & Challenges for the Clinical Research Industry, New Webinar Hosted by Xtalks 2
... and NEW YORK, Sept. 17 ,Microbia, Inc. ... ), today announced,that they have entered into ... to,co-develop and co-market Microbia,s first-in-class compound linaclotide.,Linaclotide ... of,constipation-predominant irritable bowel syndrome (IBS-C), chronic,constipation (CC), ...
... Experience in Pulmonary and Infectious Disease ... ... a,clinical stage biopharmaceutical company focused on developing products to,overcome issues of ... Company,s Chief Medical Officer. Dr. Loutit,joins Mpex from InterMune, Inc. where ...
... Sept. 17 Kyphon Inc.,(Nasdaq: KYPH ... clearance from the,Federal Trade Commission (FTC) and ... Improvements Act of 1976 (as amended) with,respect ... assets,and associated intellectual property rights of Disc-O-Tech ...
Cached Biology Technology:Microbia and Forest Laboratories Announce Linaclotide Co-Development and Co-Marketing Collaboration 2Microbia and Forest Laboratories Announce Linaclotide Co-Development and Co-Marketing Collaboration 3Microbia and Forest Laboratories Announce Linaclotide Co-Development and Co-Marketing Collaboration 4Microbia and Forest Laboratories Announce Linaclotide Co-Development and Co-Marketing Collaboration 5Mpex Pharmaceuticals Names Dr. Jeffery Loutit as Chief Medical Officer 2Mpex Pharmaceuticals Names Dr. Jeffery Loutit as Chief Medical Officer 3Federal Trade Commission Clears Kyphon's Acquisition of Non-Vertebroplasty Spine-Related Assets of Disc-O-Tech 2
(Date:8/19/2014)... parts of the world, leprosy and tuberculosis live ... of leprosy per year, with nearly all of ... available century-old vaccine Bacille Calmette-Guerin, or BCG, provides ... so a more potent vaccine is needed to ... a stronger weapon against both diseases., In a ...
(Date:8/19/2014)... Aug. 19, 2014 ) -- Scientists at the Houston ... up and transfer single cells using a pipette -- ... describe this engineering feat and preliminary test results in ... American Chemical Society . , "Studying single cells and ... biomedical research," said nanomedicine department. faculty member Lidong Qin, ...
(Date:8/19/2014)... been awarded a nearly $40,000 grant from the National ... of the National Park Service (NPS) and U.S. Department ... study of the energy efficiency and cost effectiveness of ... climates. , Radiant barriers are reflective thermal insulations commonly ... thereby reducing the amount of heat emitted in the ...
Breaking Biology News(10 mins):New vaccine shows promise as stronger weapon against both tuberculosis and leprosy 2Moving single cells around -- accurately and cheaply 2UTSA researcher awarded $38K+ to evaluate energy efficiency options for historic homes 2UTSA researcher awarded $38K+ to evaluate energy efficiency options for historic homes 3
... Despite ongoing public health efforts, E. coli ... sickness and death throughout the world. But the ... published today in the scientific journal Nature , researchers ... discovered a molecule,s previously unknown role in fighting off ...
... of North Carolina scientists have uncovered a new strategy ... and chronic obstructive pulmonary disorder better clear the thick ... to life-threatening infections. In a new report appearing online ... researchers show that the "SPLUNC1" protein and its derivative ...
... July 13, 2012, Shenzhen, China - An international team, ... Academy of Science, and BGI, the world,s largest genomics ... salt cress ( Thellungiella salsuginea ), a wild salt-tolerant ... tool for exploring mechanisms of adaptive evolution and sheds ...
Cached Biology News:La Jolla institute identifies critical cell in fighting E. coli infection 2La Jolla institute identifies critical cell in fighting E. coli infection 3New proteins to clear the airways in cystic fibrosis and COPD 2Salt cress genome yields new clues to salt tolerance 2
Green Standard is fluorescein....
Red Standard is sodium salt of resorufin....
Human Jagged 2 Biotinylated Affinity Purified PAb...
RayBio L Series 507: RayBio Label-based Antibody Array I (2 membranes) Class: Antibody Array Products Product Group: Antibody Array...
Biology Products: